Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
“Evaluation processes are ongoing within the Company and with external partners to optimise the development and large-scale manufacturing, with an active marketing strategy to follow”
LARGE SCALE 👀
Did APTA just revolutionise clinical diagnostics
Dr Arron Tolley, Chief Technical Officer of Aptamer Group, said: "Since we received the proceeds of the September fundraise, the team has worked hard to accelerate the development of Optimer®+ and to show the new platform's capabilities. The development of this platform is integral to our mission to stay at the forefront of binder technologies. Both the lab-based research and the initial animal experiments suggest that Optimer®+ will be well placed to deliver the next generation of binders to enable the targeted delivery of precision medicines. This is an area where we are seeing increasing interest due to the unmet needs across gene therapy and precision chemotherapy."
Https://x.com/theunsophistic2/status/1762117653475233868?s=46&t=4s-AQzZhMmeWz3Ire1AEsA
The business counts three-quarters of the world’s top 20 pharmaceutical companies among its clients, including Japan’s largest drugmaker, Takeda. It is working with the UK’s top drugs firm, AstraZeneca, on kidney disease treatments; with Cancer Research UK to develop aptamers as targeted treatments for chronic myelomonocytic leukaemia, a rare type of blood cancer; with South Korea’s PinotBio to develop precision chemotherapy treatments; and with Gene Therapeutics in the US to create gene therapies.
https://aptamergroup.com/aptamer-and-pinotbio-collaborate-to-develop-new-therapeutic-drug-conjugates/
Aptamer Group is working on many important diagnostic and therapeutic targets to support its customers and collaborators, including Cancer Research UK and AstraZeneca to develop targeted drug delivery for kidney disease.
APTA
Today we announce a trading update for H1.
Highlights include:
✅ £1.4M signed deals to date to be progressed through the laboratories
💰 Cash reserves of £2.1M at the end of Jan
🧬 Strong progress in targeted delivery vehicles for gene therapy with a top pharma partner
🔬 Internal success with generation of IHC data and binders trialled by a top 5 pharma partner showing promise
🎯 £1.5M deals at advanced stage negotiations.
Https://www.business-live.co.uk/technology/york-life-sciences-pioneer-aptamer-28682556.amp
Thing is, that was unexpected and on the face of it nothingness news. (But potentially game changing)
Seller took it below 1p
Safe to assume their finished
Held its gains and should build strong from here no pump and dump
Strong progress in discovery and validation has continued, delivering new binders that demonstrate the performance of the Optimer-Fc platform. Developed binders for IHC are now undergoing external validation by a top 5 pharma company, with initial results reported as promising and leading to a commercial request for more material. A patent application covering this platform has now been submitted.